Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects

References

• Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. Aids. 2013;27:973–979. doi:10.1097/QAD.0b013e32835cae9c23698063
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45:1074–1081. doi:10.1086/52193517879928
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735. doi:10.1056/NEJMc06319017460226
   PubMed Web of Science ®Google Scholar
• Nolan D, Hammond E, Martin A, et al. DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003;17:1329–1338. doi:10.1097/01.aids.0000060385.18106.3512799554
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–8.9619798
   PubMed Web of Science ®Google Scholar
• Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–531. doi:10.1097/QAI.000000000000152528825943
   PubMed Web of Science ®Google Scholar
• Menard A, Meddeb L, Tissot-Dupont H, et al. Dolutegravir and weight gain: an unexpected bothering side effect? AIDS. 2017;31(10):1499–1500. doi:10.1097/QAD.000000000000149528574967
   PubMed Web of Science ®Google Scholar
• Debroy P, Sim M, Erlandson KM, et al. Modena HIV metabolic cohort team. Progressive increases in fat mass occur in adults living with HIV on antiretroviral therapy, but patterns differ by sex and anatomic depot. J Antimicrob Chemother. 2019 [Epub ahead of print]. doi:10.1093/jac/dky551
   PubMed Web of Science ®Google Scholar
• Pavie J, Porcher R, Torti C; on behalf of the NEAT Unboosted Atazanavir Cohort Study Group, et al. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother. 2011;66(10):2372–2378. doi:10.1093/jac/dkr31621821627
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of health and human services. Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 3, 9 2019.
   Google Scholar
• Eron JJ, Young B, Cooper DA, et al. SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396–407. doi:10.1016/S0140-6736(09)62041-920074791
   PubMed Web of Science ®Google Scholar
• Martínez E, Larrousse M, Llibre JM; SPIRAL Study Group, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24(11):1697–1707. doi:10.1097/QAD.0b013e32833a608a20467288
   PubMed Web of Science ®Google Scholar
• Potard V, Simon A, Lacombe JM, Parienti JJ, Costagliola D; French Hospital Database on HIV (FHDH-ANRS CO4). Switching to raltegravir from a virologically effective boosted protease inhibitor regimen: a comparative effectiveness analysis from the french hospital database on HIV (FHDH-ANRS CO4). Clin Infect Dis. 2016;63(9):1254–1261. doi:10.1093/cid/ciw49827543648
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014;14(7):581–589. doi:10.1016/S1473-3099(14)70782-024908551
   PubMed Web of Science ®Google Scholar
• Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study. Antivir Ther. 2017;22(4):295–305. doi:10.3851/IMP316628401876
   PubMed Web of Science ®Google Scholar
• Gatell JM, Assoumou L, Moyle G; NEAT022 Study Group, et al. Immediate vs. deferred switching from a Boosted Protease Inhibitor (PI/r) Based Regimen to a Dolutegravir (DTG) based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: final 96 weeks results of NEAT 022 study. Clin Infect Dis. 2018. doi:10.1093/cid/ciy505
   Web of Science ®Google Scholar
• Raffi F, Esser S, Nunnari G, Pérez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med. 2016;17(Suppl 5):3–16. doi:10.1111/hiv.12440
   PubMed Web of Science ®Google Scholar
• Andreoni M, Marcotullio S, Puro V, et al. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaimProject. New Microbiol. 2015;38(4):443–490.26571377
   PubMed Web of Science ®Google Scholar
• D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–753. doi:10.1161/CIRCULATIONAHA.107.69957918212285
   PubMed Web of Science ®Google Scholar
• de Boer MG, van Den Berk GE, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016;30(18):2831–2834. doi:10.1097/QAD.000000000000127927824625
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63. doi:10.1111/hiv.1246827860104
   PubMed Web of Science ®Google Scholar
• Lepik KJ, Yip B, Ulloa AC, et al. Adverse drug reactions to integrase strand transfer inhibitors. AIDS. 2018;32(7):903–912. doi:10.1097/QAD.000000000000178129424784
   PubMed Web of Science ®Google Scholar
• Hill AM, Mitchell N, Hughes S, Pozniak AL. Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials. Curr Opin HIV AIDS. 2018;13(2):102–111. doi:10.1097/COH.000000000000044529278532
   PubMed Web of Science ®Google Scholar
• Huang W, Frantzell A, Fransen S, Petropoulos CJ. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob Agents Chemother. 2013;57(9):4105–4113. doi:10.1128/AAC.00204-1323733474
   PubMed Web of Science ®Google Scholar
• Lucas GM, Cheever LW, Chaisson RE, Moore. RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection J. Acq Immune Def Synd. 2001;27:251–259. doi:10.1097/00042560-200107010-00006
   PubMed Web of Science ®Google Scholar
• Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral–based therapy. Clin Infect Dis. 2013;57(Suppl 2):S118–S124. doi:10.1093/cid/cit32623884059
   PubMed Web of Science ®Google Scholar
• Mills A, Crofoot G, Ortiz R, et al. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. HIV Clin Trials. 2014;15(2):51–56. doi:10.1310/hct1502-5124710918
   PubMed Web of Science ®Google Scholar
• Baldin G, Ciccullo A, Capetti A, et al. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study. HIV Med. 2019;20(2):164–168. doi:10.1111/hiv.1268830457197
   PubMed Web of Science ®Google Scholar
• Di Biagio A, Lorenzini P, Gustinetti G, et al. Durability of second antiretroviral regimens in the italian cohort naïve antiretrovirals foundation study and factors associated with discontinuation. AIDS Patient Care STDS. 2017;31(12):487–494. doi:10.1089/apc.2017.014029211512
   PubMed Web of Science ®Google Scholar
• Boyd MA, Moore CL, Molina JM; SECOND-LINE study group, et al. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV. 2015;Feb(2):e42–51. doi:10.1016/S2352-3018(14)00061-7
   Web of Science ®Google Scholar
• Blanco JL, Gonzalez-Cordón A, Llibre JM, et al. Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir. Antivir Ther. 2015;20(5):487–492. doi:10.3851/IMP281224964358
   PubMed Web of Science ®Google Scholar
• Geretti AM, Smith C, Haberl A, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008;13(7):927–936.19043927
   PubMed Web of Science ®Google Scholar
• Martínez E, D’Albuquerque PM, Llibre JM; SPIRAL Trial Group, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012;26(18):2315–2326. doi:10.1097/QAD.0b013e328359f29c23018438
   PubMed Web of Science ®Google Scholar
• Bernal E, Masiá M, Padilla S, Gutiérrez F. High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDS. 2008;22(7):569–575. doi:10.1089/apc.2007.018618479224
   PubMed Web of Science ®Google Scholar
• Pascot A, Lemieux I, Bergeron J, et al. HDL particle size: a marker of the gender difference in the metabolic risk profile. Atherosclerosis. 2002;160(2):399–406.11849664
   PubMed Web of Science ®Google Scholar
• Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781–1784. doi:10.1097/QAD.0b013e32833ad8b420495438
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Bracciale L, Doino M, et al. Lipid-lowering effect of tenofovir in HIV-infected patients. J Antimicrob Chemother. 2011;66(3):682–683. doi:10.1093/jac/dkq46421131692
   PubMed Web of Science ®Google Scholar
• Taramasso L, Ricci E, Menzaghi B; CISAI Study Group, et al. Weight gain: a possible side effect of all antiretrovirals. Open Forum Infect Dis. 2017;4(4):ofx239. doi:10.1093/ofid/ofx23929255735
   PubMed Web of Science ®Google Scholar
• Gibson A, Spivak A, Presson A, Jamjian C. 549. weight and BMI changes in HIV-infected virologically suppressed adults after switching to an elvitegravir- or dolutegravir-containing regimen. Open Forum Infect Dis. 2018;5(Suppl1):S204. doi:10.1093/ofid/ofy210.557
   Google Scholar
• Landovitz RJ, Zageneh SZ, Chau G et al. Cabotegravir is not associated with weight gain in HIV-negative individuals: HPTN077. OC 34 LB. CROI Seattle March 4- 72019.
   Google Scholar
• Smolders EJ, Smit C, de Kanter C, et al. ATHENA national HIV observational cohort. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect. HIV Med. 2018;19(3):216–226. doi:10.1111/hiv.1257029194939
   PubMed Web of Science ®Google Scholar
• Baril J, Conway B, Giguère P, Ferko N, Hollmann S, Angel JB. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction. HIV Med. 2014;15(5):301–310. doi:10.1111/hiv.1211824314017
   PubMed Web of Science ®Google Scholar
• Giacomelli A, Oreni L, Franzetti M, et al. Factors involved in continuance of atazanavir-based regimens: results from a cohort of HIV1-positive patients. Antiviral Res. 2016;129:52–57. doi:10.1016/j.antiviral.2016.02.01026902109
   PubMed Web of Science ®Google Scholar
• Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol. 2017;22(8):6–14.
   Google Scholar
• Taramasso L, Tatarelli P, Ricci E, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018;18(1):357. doi:10.1186/s12879-018-3109-630064371
   PubMed Web of Science ®Google Scholar
• Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013;8(3):e59551. doi:10.1371/journal.pone.005955123555704
   PubMed Web of Science ®Google Scholar
• Cerrato E, Calcagno A, D’Ascenzo F, et al Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Heart. 2015;2:e000174. doi:10.1136/openhrt-2014-00017425815207
   PubMedGoogle Scholar